thalidomide has been researched along with Nevoxanthoendothelioma in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation--metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma--in pediatric patients." | 3.78 | Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. ( Bailey, KM; Castle, VP; Hummel, JM; McAllister-Lucas, LM; Moyer, J; Piert, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, KM | 1 |
| Castle, VP | 1 |
| Hummel, JM | 1 |
| Piert, M | 1 |
| Moyer, J | 1 |
| McAllister-Lucas, LM | 1 |
1 other study available for thalidomide and Nevoxanthoendothelioma
| Article | Year |
|---|---|
Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.
Topics: Adolescent; Child; Female; Histiocytic Sarcoma; Humans; Immunosuppressive Agents; Michigan; Precurso | 2012 |